STS Apologizes for Ex-President's Speech Amid Twitter Backlash STS Apologizes for Ex-President's Speech Amid Twitter Backlash
A speech at the Society of Thoracic Surgeons ' annual meeting, delivered by its outgoing president, sparked outrage and dismay on social media and prompted an unusual public apology from the group.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 27, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

Society Responds to Outgoing President's Remarks on Diversity
(MedPage Today) -- Following the Society of Thoracic Surgeons (STS) annual meeting in San Diego earlier this week, the organization's leadership has responded to controversial comments made by its outgoing president, John Calhoon, MD, of UT Health... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 25, 2023 Category: American Health Source Type: news

Now, a Surgical Risk Model Tailored to Adult Congenital Heart Disease
(MedPage Today) -- SAN DIEGO -- The growing population of adults with congenital heart disease (CHD) now has a dedicated operative risk algorithm for cardiac surgery, model developers reported. Incorporating 47 newer diagnosis- and procedure... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 24, 2023 Category: Cardiology Source Type: news

Carotid Plaque & Hearing Loss; Exercise Intervention for Afib; MitraClip Lock Issue
(MedPage Today) -- In the Atherosclerosis Risk in Communities cohort, people with carotid atherosclerosis in mid-life were more likely to have worse hearing decades later. (JAMA Otolaryngology-Head & Neck Surgery) Higher HDL cholesterol corresponded... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 24, 2023 Category: Cardiology Source Type: news

Bypass Surgery for Multivessel CAD Reaffirmed in Newer Data
(MedPage Today) -- SAN DIEGO -- The recently weakened endorsement of coronary artery bypass grafting (CABG) for multivessel disease is not supported by contemporary real-world data, heart surgeons argued. Based on over 100,000 Medicare beneficiaries... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 23, 2023 Category: Cardiology Source Type: news

Baylor Study: Mesothelioma ‘Staged Surgical Approach’ Increases Survival
In this study, there were no immediate deaths following the first surgery, and all 14 patients proceeded to the second surgery. There were two patients – both starting with the EPP – who died within 90 days of the abdominal surgery. “When considering bicavitary cytoreductive surgery for mesothelioma, we would recommend only performing ePD and avoiding EPP in this cohort of patients,” authors concluded. Baylor Medical Center thoracic surgeon Dr. R. Taylor Ripley was the lead author of the study. One of the co-authors was surgical oncologist Dr. Paul Sugarbaker, brother of Dr. David Sugarbaker and a pioneer in ...
Source: Asbestos and Mesothelioma News - January 4, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news

Mesothelioma Surgery With Immunotherapy Proves Effective in Study
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine. The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective. This randomized clinical trial compared the use of durvalumab alone – already shown to be effective in other cancers – to both the two-drug combination and to using no immunotherapy before mesothelioma surgery. Clinica...
Source: Asbestos and Mesothelioma News - December 19, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news

Prior SARS-CoV-2 Infection Not Linked to Worse Outcomes After Surgery
FRIDAY, Dec. 16, 2022 -- Prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not associated with death, major adverse cardiovascular events, or rehospitalization following elective major noncardiac surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 16, 2022 Category: Pharmaceuticals Source Type: news

Postop CV Morbidity Down With Increased Time From COVID-19 to Surgery
WEDNESDAY, Dec. 14, 2022 -- The odds of experiencing major postoperative cardiovascular morbidity are reduced with increased time from COVID-19 diagnosis to surgery, according to a study published online Dec. 14 in JAMA Network Open. John M. Bryant,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2022 Category: Pharmaceuticals Source Type: news

Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Bariatric Surgery Cuts CVD Risk in Patients With Obesity, NAFLD
WEDNESDAY, Nov. 23, 2022 -- Bariatric surgery is associated with a significant reduction in cardiovascular disease (CVD) risk among individuals with severe obesity and nonalcoholic fatty liver disease (NAFLD), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2022 Category: Pharmaceuticals Source Type: news

American Heart Association, Nov. 5-7
The annual meeting of the American Heart Association was held this year from Nov. 5 to 7 and attracted participants from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 23, 2022 Category: General Medicine Source Type: news

Looking Beyond Clinical Trials for Mesothelioma Treatment
Clinical trial results should not always be the guiding force when a mesothelioma cancer patient and their medical team determine what therapy path to take, according to one recent study. A look at real-world populations might be just as important. A research team at the University of Pennsylvania Department of Medicine has made the point with a retrospective, observational analysis of second-line treatment for pleural mesothelioma. The analysis came on the heels of a multicenter clinical trial from the European Thoracic Oncology Platform that evaluated the efficacy of pembrolizumab (Keytruda), an immunotherapy drug,...
Source: Asbestos and Mesothelioma News - November 22, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news